已收盤 11-20 16:00:00 美东时间
-0.610
-4.29%
Clinical-stage precision oncology company Erasca Inc. (NASDAQ:ERAS) on Friday shared updated U.S. Phase 1 monotherapy and initial combination results for its pan-RAS molecular glue ERAS-0015. The company also released early Phase 1 monotherapy data for pan-KRAS inhibitor ERAS-4001. • What is going o...
11-20 23:40
The latest announcement is out from Erasca ( ($ERAS) ). On November 20, 2026, E...
11-20 20:29
Bristol-Myers Squibb (NYSE:BMY) reported broad clinical momentum across hematology and central nervous system programs in November 2026. At the 68th ASH Annual Meeting, the drugmaker presented five-year Breyanzi data in second-line large B-cell lymphoma, as well as new CELMoD and dual-targeting CAR T findings in multiple myeloma. The pipeline update included preliminary Phase 3 KarXT results in Alzheimer’s psychosis, an Evotec protein degradation
11-20 14:14
今日重点评级关注:Ascendiant Capital:维持Allarity Therapeutics"买入"评级,目标价从11美元升至11.25美元;康托·菲茨杰拉德:维持Cypherpunk Technologies"超配"评级,目标价从4.9美元升至5美元
11-18 15:28
Leerink Partners initiates coverage on Erasca (NASDAQ:ERAS) with a Outperform rating and announces Price Target of $35.
11-17 23:39
Erasca shares are trading lower after the company reported worse-than-expected Q3 EPS results.
11-14 00:01
Tango Therapeutics and Erasca have launched a Phase 1/2 trial combining vopimetostat, a PRMT5 inhibitor, with ERAS-0015, a pan-RAS molecular glue, to treat MTAP-deleted pancreatic cancer and MTAP-deleted/RAS-mutant non-small cell lung cancer. The study aims to assess safety, tolerability, and antitumor activity of this combination. Both companies believe targeting PRMT5 and RAS together could offer a promising approach for these cancers.
11-04 13:30
Erasca, a precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers, announced its management will participate in three investor conferences in November 2026: Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 10, Stifel 2026 Healthcare Conference in New York on November 11, and Jefferies Global Healthcare Conference in London on November 18. Each event will feature a fireside chat, with live au...
11-03 13:00
Propanc Biopharma announced new preclinical data supporting PRP's potential to address chemotherapy resistance in pancreatic cancer. PRP, a proprietary enzyme formulation, demonstrated anti-tumor activity, EMT reversal, and chemosensitization in preclinical models. Key findings include reduced cancer cell proliferation, inhibited metastasis, and enhanced response to chemotherapy. PRP's mechanism targets cancer stem cells and fibrosis, complementi...
10-26 12:30